Axonics, Inc. (NASDAQ:AXNX) Receives Average Recommendation of "Hold" from Brokerages

Axonics, Inc. (NASDAQ:AXNX - Get Free Report) has been assigned an average rating of "Hold" from the eight analysts that are covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a hold recommendation. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $71.00.

Separately, Needham & Company LLC reissued a "hold" rating on shares of Axonics in a research note on Friday, November 8th.

Insiders Place Their Bets

In other news, CFO Kari Leigh Keese sold 2,961 shares of Axonics stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total value of $205,523.01. Following the transaction, the chief financial officer now owns 40,362 shares of the company's stock, valued at $2,801,526.42. The trade was a 6.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.85% of the company's stock.

Institutional Investors Weigh In On Axonics

Large investors have recently modified their holdings of the business. Edgestream Partners L.P. purchased a new position in Axonics in the first quarter valued at approximately $605,000. Janus Henderson Group PLC increased its position in Axonics by 637.7% during the 1st quarter. Janus Henderson Group PLC now owns 178,322 shares of the company's stock worth $12,298,000 after purchasing an additional 154,149 shares in the last quarter. Gabelli Funds LLC purchased a new stake in Axonics in the 1st quarter valued at about $12,271,000. Cowen AND Company LLC purchased a new stake in shares of Axonics during the 2nd quarter worth about $605,000. Finally, Bank of New York Mellon Corp lifted its position in Axonics by 12.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,171 shares of the company's stock worth $14,668,000 after acquiring an additional 23,460 shares in the last quarter. Hedge funds and other institutional investors own 99.48% of the company's stock.

Axonics Trading Up 0.8 %

Shares of NASDAQ:AXNX traded up $0.53 during trading on Friday, reaching $70.98. The stock had a trading volume of 4,233,308 shares, compared to its average volume of 381,251. Axonics has a 52 week low of $55.09 and a 52 week high of $71.05. The stock has a fifty day simple moving average of $69.83 and a two-hundred day simple moving average of $68.54.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.